Please login to the form below
chronic low back pain
This page shows the latest chronic low back pain news and features for those working in and with pharma, biotech and healthcare.
Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
The 16-week study in patients with osteoarthritis (OA) pain evaluated subcutaneous administration of tanezumab, one of a new class of nerve growth factor (NGF) inhibitor drugs. ... In addition to OA pain, the biologic is being evaluated for chronic low
Latest news
-
FDA fast-tracks Pfizer and Lilly's tanezumab
pain. The US FDA gave the status to tanezumab as a treatment for osteoarthritis and chronic low back pain in patients who cannot adequate pain relief or cannot tolerate currently available ... potential. They estimate that there are more than 27 million
-
FDA halts study of Teva and Regeneron's pain drug fasinumab
The FDA placed a clinical hold on a phase IIb trial of Teva and Regeneron's nerve growth factor (NGF) inhibitor fasinumab in chronic lower back pain on safety concerns. ... We look forward to working with global health authorities to advance this
-
Pfizer sales down but oncology shows promise
pegged back by the termination of a collaboration with Boehringer Ingelheim on chronic obstructive pulmonary disease (COPD) treatment Spiriva (tiotropium) in some markets. ... The company has also joined forces with Lilly to develop anti-nerve growth
-
Lilly's Cymbalta approved for new use
osteoarthritis and chronic lower back pain. ... The marketing application for the latest indication was supported by relatively small clinical studies enrolling about 600 patients with chronic low back pain or chronic pain due to osteoarthritis who
-
FDA advisors back expanded Cymbalta use
broader population after reviewing safety and efficacy data from studies testing the drug for chronic low back pain and for chronic pain due to osteoarthritis of the knee. ... For people living with chronic low back pain and chronic pain due to
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch table for November 2013
prostate cancer. 2, 400. Pfizer / Lilly. Co-development. Shared development of tanezumab (anti-nerve growth factor) for the treatment of osteoarthritis, chronic low back and cancer pain. ... hyperactivity disorder, pain, urology and allergy. 1, 600.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Senior Account Manager
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Medical Editor
-
Competitive
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Celltrion’s investigational mAb cuts COVID-19 recovery time
- New study identifies drugs that are safe to use in COVID-19 treatment
- UK pharmacies to begin administering COVID-19 vaccinations
- PHE study finds people who have had COVID-19 can still transmit the virus
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- EU proposes vaccine-sharing mechanism with low-income countries
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- WHO’s director-general deems vaccine nationalism a “catastrophic moral failure”
- Lilly partners with Merus on development of bispecific antibodies for cancer
- Medical research charities need our help – support is needed to continue funding life-saving research and improving lives
- Research Partnership appoints Hannah Osborn to MedTech director role
PMHub
Hamell
Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...
Latest intelligence
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
- The search for effective drug treatments for COVID-19
- PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
Quick links
Infographics
